ADC antibody conjugated drugs are formed by connecting highly specific monoclonal antibodies (antibodies) with highly active small molecule toxic drugs (payloads) through linkers. For tumor treatment, it has the advantages of high targeting, strong specificity, and low toxicity and side effects. After ADC drugs enter the body, the antibody part binds to the targeted antigen on the surface of tumor cells, and the tumor cells will internalize ADC molecules. Afterwards, ADC drugs will decompose in lysosomes, releasing active chemotherapeutic toxins that can damage DNA or prevent tumor cell division, thereby killing cells. An ideal ADC antibody conjugated drug requires a perfect combination of four parts: antigen, antibody, toxin molecule, and linker.